 |
|
Use of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment
Desmond Y. H. Yap, Kevin S. H. Liu, Yu-Chun Hsu, Grace L. H. Wong, Ming-Chang Tsai, Chien-Hung Chen, Ching-Sheng Hsu, Yee Tak Hui, Michael K. K. Li, Chen-Hua Liu, Yee-Man Kan, Ming-Lung Yu, Man-Fung Yuen
Clin Mol Hepatol. 2020;26(4):554-561. Published online 2020 Aug 28 DOI: https://doi.org/10.3350/cmh.2020.0058
|
|
Citations to this article as recorded by
 The efficacy and safety of direct-acting antiviral regimens for end-stage renal disease patients with HCV infection: a systematic review and network meta-analysis
Ruochan Chen, Yinghui Xiong, Yanyang Zeng, Xiaolei Wang, Yinzong Xiao, Yixiang Zheng
Frontiers in Public Health.2023;[Epub] CrossRef Glecaprevir/Pibrentasvir and Renal Dysfunction in Deceased Donor Renal Transplantation: A Case Report
Akari Kaba, Shigeyoshi Yamanaga, Yuji Hidaka, Mariko Toyoda, Masayuki Kashima, Yoshi Takekuma, Akito Inadome, Hiroshi Yokomizo, Akira Miyata
Transplantation Proceedings.2022; 54(2): 549. CrossRef Real-world effectiveness and safety of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for genotype 6 chronic hepatitis C
Jyh-Jou Chen, Yen-Cheng Chiu, Pei-Lun Lee, Hung-Da Tung, Hung-Chih Chiu, Shih-Chieh Chien, Pin-Nan Cheng
Journal of the Formosan Medical Association.2022; 121(11): 2265. CrossRef Pan-genotypic direct-acting antivirals for patients with hepatitis C virus infection and chronic kidney disease stage 4 or 5
Chen-Hua Liu, Jia-Horng Kao
Hepatology International.2022; 16(5): 1001. CrossRef Safety and effectiveness of direct-acting antivirals in patients with chronic hepatitis C and chronic kidney disease
Ji Eun Ryu, Myeong Jun Song, Seok-Hwan Kim, Jung Hyun Kwon, Sun Hong Yoo, Soon Woo Nam, Hee Chul Nam, Hee Yeon Kim, Chang Wook Kim, Hyun Yang, Si Hyun Bae, Do Seon Song, U Im Chang, Jin Mo Yang, Sung Won Lee, Hae Lim Lee, Soon Kyu Lee, Pil Soo Sung, Jeong
The Korean Journal of Internal Medicine.2022; 37(5): 958. CrossRef Recent Information on Pan-Genotypic Direct-Acting Antiviral Agents for HCV in Chronic Kidney Disease
Fabrizio Fabrizi, Federica Tripodi, Roberta Cerutti, Luca Nardelli, Carlo M. Alfieri, Maria F. Donato, Giuseppe Castellano
Viruses.2022; 14(11): 2570. CrossRef Drug-drug interactions with direct-acting antivirals — less is more
Grace Lai-Hung Wong
Clinical and Molecular Hepatology.2021; 27(1): 81. CrossRef More evidence that direct acting antiviral therapy is safe and effective in cirrhosis and chronic kidney disease including peritoneal dialysis
Paul Kwo, Deepti Dronamraju
Clinical and Molecular Hepatology.2020; 26(4): 489. CrossRef
|